6533b827fe1ef96bd1286728

RESEARCH PRODUCT

CT and MR imaging of chemotherapy-induced hepatopathy.

Filippo BarbieraGiuseppe BadalamentiMarco Dioguardi BurgioMassimo MidiriValérie VilgrainSilvestro CusmàFederica VernuccioGiuseppe Brancatelli

subject

medicine.medical_specialtyUrologymedicine.medical_treatment030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibrosisInternal medicineParenchymamedicineHumansRadiology Nuclear Medicine and imagingHepatitisChemotherapyRadiological and Ultrasound Technologymedicine.diagnostic_testChemotherapy Hepatopathy Computed tomography Magnetic resonance imaging Sinusoidal obstruction syndromebusiness.industryGastroenterologyMagnetic resonance imagingHepatologymedicine.diseaseMr imagingMagnetic Resonance Imaging030220 oncology & carcinogenesissense organsRadiologySteatosisChemical and Drug Induced Liver InjurybusinessTomography X-Ray Computed

description

Chemotherapy-induced hepatopathy includes a wide variety of parenchymal and vascular hepatic changes on imaging, including diffuse or focal hepatopathies (i.e. hepatitis, steatosis, fibrosis, pseudocirrhosis, or sinusoidal obstruction). These changes can profoundly alter the hepatic parenchyma on imaging and result in both false negative and false-positive diagnoses of hepatic metastases and lead to errors in patient management strategies. It is therefore important for radiologists to have a comprehensive knowledge of the imaging patterns that may develop following chemotherapy. The purpose of this review is to explore the broad spectrum of hepatic parenchymal and vascular chemotherapy-induced changes on CT and MR imaging.

yearjournalcountryeditionlanguage
2019-08-23Abdominal radiology (New York)
10.1007/s00261-019-02193-yhttps://pubmed.ncbi.nlm.nih.gov/31435760